Neuphoria Therapeutics Inc's Business Segments

Neuphoria Therapeutics Inc., formerly Bionomics Limited, is a Delaware corporation listed on the Nasdaq Global Market. The company re-domiciled from Australia to Delaware in late 2024, becoming the successor issuer to Bionomics. Operating in the biotechnology sector, Neuphoria focuses on drug discovery and development, conducting clinical trials and preclinical studies to assess the safety and efficacy of its product candidates. The company plans to commercialize these candidates, targeting specific geographic regions and patient populations. Neuphoria relies on third parties for clinical trials and manufacturing and seeks to protect its intellectual property rights. It faces risks related to regulatory approvals, competition, financial performance, and cybersecurity. The company reports under U.S. GAAP in U.S. dollars, with a fiscal year ending June 30, and transitioned to reporting as a domestic U.S. issuer as of July 1, 2024. Neuphoria uses trademarks including Neuphoria™ and Bionomics™ in its operations and filings.

The Company operates as a single operating and reporting segment focused on the discovery and development of allosteric ion channel modulators for central nervous system disorders with high unmet medical need. The chief operating decision maker (CODM) evaluates operating performance based on net income (loss) reported on the consolidated statement of operations and measures operating segment assets as total assets reported on the consolidated balance sheet.